Aspira Women's Health reports Q4 2022 preliminary volumes up 18%; expects $6M cost savings

Aspira Women's Health Inc.

2022-FY EPS reported -$0.23 revenue$8,184,000

Q4 2022 OvaSuite test volume 5,643 (+18% YoY); full-year 2022 volume 21,424 (+23% YoY).
Achieved previously provided Q4 cash utilization guidance of $6-8 million.
Anticipates ~$6M in cost savings from staff reductions; does not expect material impact on growth.
Expanded territories for top field reps; optimizing BioReference co-marketing agreement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Aspira Women's Health Inc. updated its the year ended December 31, 2022 guidance (reaffirmed).

Period: the year ended December 31, 2022
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Aspira Women's Health Inc. issued a press release announcing certain operational metrics for the fourth quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Aspira Women's Health Inc. updated its the three months ended December 31, 2021 guidance (reaffirmed).

Period: the three months ended December 31, 2021
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Aspira Women's Health Inc. issued a press release announcing certain operational metrics for the fourth quarter of 2022.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-23-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.